NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) reported Thursday that its ongoing Phase 2 study of investigational Tilrekimig met its primary endpoint in adults with moderate to severe atopic dermati...
Pfizer’s Tilrekimig Meets Phase 2 Primary Endpoint In Atopic Dermatitis
Source: Finanznachrichten.de
Read Full Story →